Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics
08:45am, Sunday, 31'st Dec 2023
CRISPR Therapeutics just received its first product approval from regulators. Intellia Therapeutics is targeting a similar niche, and it has rich allies.
AI and Automation Leaders for 2024: 7 Stocks to Stay Ahead of the Robot Uprising
12:09am, Saturday, 30'th Dec 2023
It's time for investors to ditch the search for the mythical crystal ball and instead embrace the algorithms when deciphering the best AI stock for your needs. As hyperbolic as it may sound, the futur
CRISPR Therapeutics sets sights on gene-editing cures for disease
07:01am, Wednesday, 27'th Dec 2023
On Dec. 8, 2023, Vertex Pharmaceuticals Inc. NASDAQ: VRTX announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for patients 12 years or older with recurrent vaso-occlusive
3 Healthcare Technology Stocks to Improve Lives in 2024
05:30am, Monday, 25'th Dec 2023
If you had to bet on two “big picture” sectors to invest in for the long haul, you can't go wrong with technology or healthcare. Both are omnipresent and, in their own ways, on the cutting edge of
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
05:02pm, Friday, 22'nd Dec 2023
CRISPR Therapeutics is becoming a big name in gene therapy. The industry is in its early growth stages, and the market could be massive in the future.
3 Money-Saving Tricks for Investing in Biotech Stocks in 2024
08:45am, Friday, 22'nd Dec 2023
By and large, biotech businesses tend to carry significant risks for investors. They're usually at risk of running out of money or their medicines not working.
I'm Begging You to Buy Stocks Before January -- Here's Why
05:30am, Friday, 22'nd Dec 2023
There are some good reasons why you should put your money to work right now instead of waiting. Your moves today could pay off over the long run.
Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?
05:27am, Friday, 22'nd Dec 2023
The stock market has been responding to the recent approval of CRISPR Therapeutics' first drug. A successful commercial launch for Casgevy could make the biotech stock a top performer in 2024, but tha
6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing Therapy
08:30am, Thursday, 21'st Dec 2023
CRISPR Therapeutics now has an approved gene therapy treatment in Casgevy. The treatment for sick cell disease received regulatory approval earlier this month.
Better Bull Market Buy: CRISPR Therapeutics vs. Pfizer Stock
05:51am, Thursday, 21'st Dec 2023
CRISPR Therapeutics just reached a major milestone: approval of its first product. Pfizer is cheap and could deliver market-beating total returns thanks to its juicy dividend.
CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief
09:43am, Wednesday, 20'th Dec 2023
Phuong Khanh Morrow, chief medical officer at gene editing company Crispr Therapeutics (NASDAQ: CRSP ), resigned unexpectedly. The move comes a month after Crispr won Food and Drug Administration (FDA
3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow
05:00am, Wednesday, 20'th Dec 2023
CRISPR Therapeutics reached a major milestone when regulators approved its gene-editing treatment. The company's growth story is just getting started.
Crispr Therapeutics chief medical officer is resigning
05:16pm, Tuesday, 19'th Dec 2023
Crispr Therapeutics CRSP, +8.84% on Tuesday said that Phuong Khanh Morrow was resigning as the gene-editing company's chief medical officer, a move that takes hold on Jan. 26. The resignation was “n
3 Genomics Stocks to Unlock the Future of Medicine
12:44pm, Tuesday, 19'th Dec 2023
Genomics is undeniably medicine's future, and genomics stocks stand to be the next big thing in healthcare as the industry matures. But the crux of the matter is when the industry will mature.
3 Biotech Stocks Most Wall Street Analysts Are Bullish About
10:31am, Monday, 18'th Dec 2023
Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.
